GMAB ▲ +16.1% - Genmab A/S
$GMAB Genmab Announces Statistically Significant, Clinically Meaningful Improvement in Overall Survival and Objective Response with Petosemtamab Combination at First Interim Analysis in First-Line R/M Patients with PD-L1+ Head and Neck Cancer
28-OCT-2026 09:40 AM ET
Share this post
More filings for $GMAB
GMAB ▲ +25.5% - Genmab A/SOct 28, 2026GMAB ▲ +19.6% - Genmab A/SOct 28, 2026GMAB ▲ +16.1% - Genmab A/SOct 28, 2026GMAB ▲ +3.5% - Genmab A/SOct 26, 2026GMAB ▲ +7.6% - Genmab A/SOct 23, 2026GMAB ▼ -1.5% - Genmab A/SOct 7, 2026
View full $GMAB filing history →💬 Comments
Loading comments…
Leave a comment